Literature DB >> 6310478

Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays.

Y Asano, P Albrecht, L K Vujcic, G V Quinnan, K Kawakami, M Takahashi.   

Abstract

Twenty-six healthy children susceptible to varicella were inoculated with the OKA strain of live attenuated varicella vaccine. All of the recipients showed good antibody responses without adverse clinical reactions. The seropositivity rate 5 years after vaccination was 100% by the enhanced neutralization test and 96% by the fluorescent antibody membrane antigen (FAMA) test. None of the recipients contracted varicella in spite of documented contact exposure. None of the children developed herpes zoster during the 5-year observation period. The results suggest that attenuated varicella vaccine has long-term protective efficacy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310478

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

3.  Differences in surface antigen expression of human fibroblasts cultured from bone marrow compared with those obtained from skin and embryo lung tissue.

Authors:  P M Ndumbe; R J Levinsky
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

4.  Persistence of protective immunity after postexposure prophylaxis of varicella with oral aciclovir in the family setting.

Authors:  T Yoshikawa; S Suga; T Kozawa; S Kawaguchi; Y Asano
Journal:  Arch Dis Child       Date:  1998-01       Impact factor: 3.791

Review 5.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 7.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

8.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

9.  Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.

Authors:  S Suga; T Yoshikawa; T Ozaki; Y Asano
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

10.  Errant processing and structural alterations of genomes present in a varicella-zoster virus vaccine.

Authors:  D A Vlazny; R W Hyman
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.